Literature DB >> 2256110

Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.

J F Reindel1, P E Ganey, J G Wagner, R F Slocombe, R A Roth.   

Abstract

A single, intravenous administration of a low dose of monocrotaline pyrrole (MCTP), a derivative of the pyrrolizidine alkaloid monocrotaline (MCT), induces progressive pulmonary hypertension and right ventricular hypertrophy (RVH) in rats. The temporal relationship between morphologic alterations, biochemical markers of lung injury, and the development of pulmonary hypertension was determined during the developing pulmonary disease. Three days after a single iv injection of 3.5 mg/kg MCTP, small increases in bronchoalveolar lavage (BAL) fluid lactate dehydrogenase (LDH) activity and accumulation in the lungs of intravenously administered 125I-bovine serum albumin (BSA) were associated with minimal to mild interstitial edema around large airways and blood vessels. By Day 5, BAL fluid LDH activity and 125I-BSA accumulation had increased further, and lung weight/body weight ratio and BAL fluid protein concentration were greater than those of control. Interstitial edema was more pronounced and involved patches of alveolar septal walls. A mild increase in numbers of mononuclear cells, including hypertrophied interstitial cells, was evident in these areas. Walls of pulmonary arteries less than 60 microns in diameter were mildly thickened. By Day 8, scattered clusters of alveolar sacs contained serous exudate, and interstitial mononuclear infiltrates were more pronounced. Mild to moderate thickening of arterial walls was apparent in small and large vessels. By Day 14, pulmonary arterial pressure was elevated and RVH was evident. Arterial walls were thickened and had hypertrophy of medial smooth muscle cells and intercellular edema, which was particularly prominent in areas with perivascular interstitial inflammation. Large patches of lung interstitium and alveolar lumens contained serous or fibrinous exudate. In summary, a single, intravenous administration of MCTP induced a delayed and progressive pulmonary microvascular leak, interstitial inflammation, and alterations in muscular blood vessels which resulted in pulmonary hypertension within 14 days. These morphologic, biochemical, and hemodynamic changes are nearly identical to alterations induced by the parent alkaloid, MCT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256110     DOI: 10.1016/0041-008x(90)90239-q

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  16 in total

1.  Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle.

Authors:  Robson Francisco Carvalho; Rafael Dariolli; Luis Antonio Justulin Junior; Mário Mateus Sugizaki; Marina Politi Okoshi; Antonio Carlos Cicogna; Sérgio Luis Felisbino; Maeli Dal Pai-Silva
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

2.  Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy.

Authors:  Robson Francisco Carvalho; Eduardo Paulino Castan; Cesar Augusto Coelho; Francis Silva Lopes; Fernanda Losi Alves Almeida; Aline Michelin; Rodrigo Wagner Alves de Souza; João Pessoa Araújo; Antonio Carlos Cicogna; Maeli Dal Pai-Silva
Journal:  J Mol Histol       Date:  2010-03-28       Impact factor: 2.611

3.  Morphological aspects of neuromuscular junctions and gene expression of nicotinic acetylcholine receptors (nAChRs) in skeletal muscle of rats with heart failure.

Authors:  Paula Aiello Tomé de Souza; Selma Maria Michelin Matheus; Eduardo Paulino Castan; Dijon Henrique Salomé Campos; Antônio Carlos Cicogna; Robson Francisco Carvalho; Maeli Dal-Pai-Silva
Journal:  J Mol Histol       Date:  2011-09-18       Impact factor: 2.611

Review 4.  The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?

Authors:  Natalie Hopkins; Paul McLoughlin
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

5.  Heart failure alters MyoD and MRF4 expressions in rat skeletal muscle.

Authors:  Robson Francisco Carvalho; Antonio Carlos Cicogna; Gerson Eduardo Rocha Campos; Francis da Silva Lopes; Mário Mateus Sugizaki; Célia Regina Nogueira; Maeli Dal Pai-Silva
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

6.  Differential morphofunctional characteristics and gene expression in fast and slow muscle of rats with monocrotaline-induced heart failure.

Authors:  Raquel Santilone Bertaglia; Joyce Reissler; Francis Silva Lopes; Walter Luiz Garrido Cavalcante; Fernanda Regina Carani; Carlos Roberto Padovani; Sergio Augusto Rodrigues; Antônio Carlos Cigogna; Robson Francisco Carvalho; Ana Angélica Henrique Fernandes; Marcia Gallacci; Maeli Dal Pai Silva
Journal:  J Mol Histol       Date:  2011-04-21       Impact factor: 2.611

7.  Down-regulation of MyoD gene expression in rat diaphragm muscle with heart failure.

Authors:  Francis da Silva Lopes; Robson Francisco Carvalho; Gerson Eduardo Rocha Campos; Mario Matheus Sugizaki; Carlos Roberto Padovani; Célia Regina Nogueira; Antonio Carlos Cicogna; Maeli Dal Pai-Silva
Journal:  Int J Exp Pathol       Date:  2008-06       Impact factor: 1.925

8.  Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry.

Authors:  Chun Zhou; Mary I Townsley; Mikhail Alexeyev; Norbert F Voelkel; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-15       Impact factor: 5.464

9.  Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats.

Authors:  M Y Farhat; M F Chen; T Bhatti; A Iqbal; S Cathapermal; P W Ramwell
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

10.  Monocrotaline pyrrole-induced changes in angiotensin-converting enzyme activity of cultured pulmonary artery endothelial cells.

Authors:  C M Hoorn; R A Roth
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.